Short Interest in Rapport Therapeutics (NASDAQ:RAPP) Declines By 17.5%

Rapport Therapeutics (NASDAQ:RAPP) was the recipient of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 1,740,000 shares, a decrease of 17.5% from the October 31st total of 2,110,000 shares. Currently, 10.0% of the company’s shares are sold short. Based on an average daily volume of 147,800 shares, the days-to-cover ratio is presently 11.8 days.

Rapport Therapeutics Trading Up 2.0 %

Shares of Rapport Therapeutics stock opened at $22.84 on Friday. Rapport Therapeutics has a 52-week low of $16.55 and a 52-week high of $29.74. The business has a 50 day moving average price of $23.12.

Institutional Investors Weigh In On Rapport Therapeutics

Large investors have recently added to or reduced their stakes in the company. Values First Advisors Inc. bought a new position in shares of Rapport Therapeutics during the third quarter valued at approximately $31,000. BNP Paribas Financial Markets purchased a new position in Rapport Therapeutics during the 3rd quarter valued at $34,000. SG Americas Securities LLC bought a new position in Rapport Therapeutics in the 3rd quarter worth $101,000. Sandia Investment Management LP purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter worth about $116,000. Finally, MetLife Investment Management LLC bought a new stake in shares of Rapport Therapeutics during the 3rd quarter valued at about $117,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.